These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14668944)

  • 21. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
    Smith LJ
    Arch Intern Med; 1996 Oct; 156(19):2181-9. PubMed ID: 8885816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
    Whatling C; McPheat W; Herslöf M
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1879-93. PubMed ID: 18041998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological inhibition of leukotriene biosynthesis: effects on the heart conductance.
    Sanak M; Dropinski J; Sokolowska B; Faber J; Rzeszutko M; Szczeklik A
    J Physiol Pharmacol; 2010 Feb; 61(1):53-8. PubMed ID: 20228415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation.
    De Caterina R; Zampolli A
    N Engl J Med; 2004 Jan; 350(1):4-7. PubMed ID: 14702420
    [No Abstract]   [Full Text] [Related]  

  • 25. [The role of leukotrienes in inflammation and leukotriene inhibitors].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role for leukotriene antagonists in atopic dermatitis?
    Chari S; Clark-Loeser L; Shupack J; Washenik K
    Am J Clin Dermatol; 2001; 2(1):1-6. PubMed ID: 11702615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
    Gautier-Veyret E; Bäck M; Arnaud C; Belaïdi E; Tamisier R; Lévy P; Arnol N; Perrin M; Pépin JL; Stanke-Labesque F
    Pharmacol Res; 2018 Aug; 134():311-319. PubMed ID: 29920371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
    Gür ZT; Çalışkan B; Banoglu E
    Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents.
    Jampilek J; Dolezal M; Opletalova V; Hartl J
    Curr Med Chem; 2006; 13(2):117-29. PubMed ID: 16472209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress.
    Ramalho T; Pereira N; Brandt SL; Serezani CH
    Adv Exp Med Biol; 2020; 1274():55-69. PubMed ID: 32894507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of asthma.
    Palmer LJ; Silverman ES; Weiss ST; Drazen JM
    Am J Respir Crit Care Med; 2002 Apr; 165(7):861-6. PubMed ID: 11934710
    [No Abstract]   [Full Text] [Related]  

  • 32. Leukotrienes, antileukotrienes and asthma.
    Montuschi P
    Mini Rev Med Chem; 2008 Jun; 8(7):647-56. PubMed ID: 18537720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma.
    Sorkness CA
    Pharmacotherapy; 1997; 17(1 Pt 2):50S-54S. PubMed ID: 9017788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.
    Dwyer JH; Allayee H; Dwyer KM; Fan J; Wu H; Mar R; Lusis AJ; Mehrabian M
    N Engl J Med; 2004 Jan; 350(1):29-37. PubMed ID: 14702425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in eicosanoid research, novel therapeutic implications.
    Haeggström JZ; Rinaldo-Matthis A; Wheelock CE; Wetterholm A
    Biochem Biophys Res Commun; 2010 May; 396(1):135-9. PubMed ID: 20494126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antileukotriene drugs: a new treatment for asthma].
    Armetti L; Nicosia S
    Boll Chim Farm; 1999 Dec; 138(11):599-605. PubMed ID: 10765473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antileukotrienes in clinical development for asthma.
    Centanni S; Santus P
    Expert Opin Investig Drugs; 2002 Jan; 11(1):49-58. PubMed ID: 11772320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Lipoxygenase: enzyme expression and regulation of activity.
    Steinhilber D
    Pharm Acta Helv; 1994 Jul; 69(1):3-14. PubMed ID: 7938075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In situ amplification of 5-lipoxygenase and 5-lipoxygenase-activating protein in allergic airway inflammation and inhibition by leukotriene blockade.
    Chu SJ; Tang LO; Watney E; Chi EY; Henderson WR
    J Immunol; 2000 Oct; 165(8):4640-8. PubMed ID: 11035107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukotriene pathway genetics and pharmacogenetics in allergy.
    Duroudier NP; Tulah AS; Sayers I
    Allergy; 2009 Jun; 64(6):823-39. PubMed ID: 19416143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.